<DOC>
	<DOC>NCT01069133</DOC>
	<brief_summary>Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.</brief_summary>
	<brief_title>Study of Rifaximin in Minimal Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Age 1865 years cirrhosis diagnosed by clinical or biopsy grounds Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests A/B, digit symbol and block design tests (NCTA, NCTB, DST and BDT) compared to age and educationmatched controls. No contraindications to MRI TIPS (transjugular intrahepatic portosystemic shunt) procedure or elective surgery planned within the next 8 weeks Current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy. Prior episodes of overt HE MMSE &lt;25 TIPS placement Unable to give informed consent. Contraindications to MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>minimal hepatic encephalopathy</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>complications</keyword>
</DOC>